Orchid Pharma Limited

Orchid Pharma reported Q2 FY26 sales of ₹194 crores, marking a 13% year-on-year decline, though showing a 13% sequential improvement over Q1 FY26. Global margins significantly compressed to 32% in Q2 from 43% in the prior quarter, leading to an EBITDA of ₹6 crores, down from ₹14 crores. This decline was primarily attributed to margin compression and inventory revaluation, as the company sold higher-priced inventory at prevailing weak market rates and increased sales in lower-realization emerging markets.

The broad antibiotics market continues to face severe strain, with management noting no signs of revival in the current financial year. Export analysis from India showed a 26% year-on-year fall in antibiotic export quantities and a 36% drop in value, indicating a persistent decline in both volume and price. Factors contributing to this downturn include an inventory overhang with customers, a muted flu season, government efforts to reduce antibiotic consumption, and geopolitical uncertainties.

The acquisition of global rights to Enmetazobactam and the trademark Exblifep has been formally completed, giving Orchid full control over its regulatory and commercial strategy worldwide. Management expects this asset to generate significant revenue and profits, with double-digit royalties from Advanz in Europe now accruing directly. Price approvals in the five largest EU markets (Germany, France, Spain, Italy, UK) are expected by the end of the calendar year, with some sales already initiated in Germany and other countries starting this quarter.

The domestic demand for Orchid's Orblicef brand continues to perform well, exceeding its one-year target, supported by a partnership with Cipla and the AMS division. Approximately 15,000 patients have been treated with over 200,000 vials sold. The AMS division, currently incurring a drag of ₹1.8 crores per quarter, is expected to breakeven by next year, with Piperacillin specifically targeted for breakeven by Q4 FY26. The division has reached 10% of the 1,200 tertiary care hospitals in India and plans to expand operations to the East from Kolkata.

The 7ACA project is progressing in line with revised timelines, with all fermentals now erected, marking a critical engineering milestone. This facility aims to strengthen API manufacturing, reduce import dependency, and deliver long-term cost synergies. The Cefiderocol project's building structure is nearly complete, with equipment deliveries underway, and it is on track for production readiness by Q4 FY26.

During the Q&A, management clarified a misunderstanding regarding the company's debt. An analyst inquired about a ₹1,000 crores increase in debt from March, but management confirmed that this was incorrect. The actual debt figure for the company was stated to be only ₹47 crores, correcting a potentially significant misperception about the company's financial leverage.